Drug intelligence / Profile preview

BPM-42522

Development stage: Discontinued
Lead developer: Berg

Overview

BPM-42522 is a **BERG oncology research code** associated with Berg's Interrogative Biology platform and reported in public sources as a discontinued antineoplastic program. The available evidence does **not** clearly identify a marketed or clinical-stage active ingredient, formulation, route, or a validated molecular target for BPM-42522 itself. Based on the source context, BPM-42522 appears to have been used as a preclinical or early research program identifier tied to anti-cancer drug discovery rather than a well-characterized, publicly disclosed therapeutic product.

Beyond the preview

Go deeper on BPM-42522.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPM-42522.

Explore the full profile